One of the key observations across pharma organizations, which is not different from others, is that organizations are getting better at building AI, but not at shipping them.
Across commercial teams, medical affairs, R&D, regulatory, market access, and digital transformation groups, there is still a shared sense that everyone is learning in real time. But there is something important to bear in mind: AI is not a side experiment or a future capability. It is becoming part of how pharma organizations think about insights, operations, decision-making, and growth.
A commercial team can spin up a working market intelligence prototype in a day. A medical affairs team can have a document synthesis tool running by Friday. The demos are impressive, the interfaces are clean and the outputs sound convincing. And then, couple of months later, most of it is still sitting in a sandbox waiting for approvals that never come, integrations that were never scoped and governance questions that were never answered.
“We use AI” no longer impresses anyone.
Clients are asking sharper questions. Internal leaders expect faster results. Commercial models are under pressure. Medical and regulatory teams are being asked to do more with greater precision. The question has moved from “Should we use AI?” to “Where do we start so it actually creates value?”
In pharma, teams can build impressive AI prototypes faster than ever. Tools like Lovable, Cursor, and Microsoft Copilot Studio have made this genuinely easy. A business analyst with no engineering background can have a working prototype of a Scientific Literature Review running before lunch. That is not an exaggeration.
The demo may look polished, the answers may sound convincing, and the interface may make the solution feel almost ready. But a polished prototype does not mean a production-ready solution.
The prototype shows what technology can do. However, it does not prove that the solution is accurate, compliant, scalable, secure, or trusted enough for real-world use.
That is where real work begins.
The Pilot Trap
Modern AI prototypes create a confidence mismatch, since the experience looks complete, and leaders often assume the remaining work is incremental. If the demo feels 80% done, the assumption is that production is only a few weeks away.
In reality, the visible demo may only represent a fraction of what it takes to operate agentic AI in a regulated enterprise environment.
The invisible work includes access controls, data security, compliance review, validation, workflow integration, observability, auditability, change management, and user adoption. In pharma, these are not administrative extras, which are the conditions for trust.
- A commercial intelligence agent that works in a sandbox but cannot connect to approved data sources will not change how decisions are made.
- A medical content agent that drafts responses but cannot support compliance review will not scale.
- A regulatory assistant that summarizes documents but cannot show what it used, why it made a recommendation, or how a human reviewed it will not pass the trust threshold.
This is why so many AI pilots stall. The technology works well enough to impress people, but the operating model was never designed to carry it into daily use.
There is also an organizational problem underneath the technical one. In most pharma teams, there is no clearly defined owner for the path from prototype to production. The data science team builds it, IT is responsible for infrastructure, the business is the end user and compliance/GenAI governance board reviews it. But nobody owns the end-to-end journey from working demo to something that runs reliably in a production environment and is actually used by the people it was built for. That gap is the absence of a role or structure that bridges all of those functions. Complex workflows like Omni-Channel or HTA Filing require deep domain understanding as well as the capability to translate them into Agents that can augment existing process rather than adding complexity or broken workflows.
Part of why this persists is how AI progress gets measured internally. Most organizations track the number of pilots launched while some track the pipeline of Agentic AI. Very few track the number of AI tools currently running in production and actively used. If the scorecard rewards starting things, the organization will get very good at starting things.
Agentic AI Raises the Stakes
Different from traditional software that follows defined rules and works in environments where requirements are written, workflows are built, outputs are tested against expected behavior, and the system ships.
Agentic systems, in comparison, are more adaptive. They reason, retrieve information, call tools, interpret context, and sometimes trigger downstream actions. Their behavior emerges from the interaction between models, tools, prompts, data, memory, and human feedback.
That creates new questions pharma teams must ask much earlier:
- What data can the agent access?
- What actions can it take?
- Where does human approval happen?
- How are outputs validated?
- What happens when an agent makes the wrong recommendation?
- How do we audit the reasoning path?
- How do we know whether people are actually using it?
That creates questions pharma teams are not used to asking before they build. What happens when the agent makes the wrong recommendation? In a traditional system, a wrong output is a bug with a traceable cause. In an agentic system, the wrong output may be perfectly reasonable given the inputs the agent had access to at that moment and reproducing the exact conditions to debug it may not be straightforward. For a commercial team, that is a concern when accurate numbers needed to be reported on sales, engagement and various leading indicators, bifurcated by indication, MoA, country, among others. Similarly, for a medical or regulatory team, such issues become a compliance event. Also, questions arrive mostly on how do you audit the reasoning path? A human analyst can explain their logic. An agent that synthesized 200 documents, called three tools and produced a recommendation needs to be able to show its work which is a regulatory requirement for use cases that demands so (e.g., HTA/Clinical Protocol/SLR etc.). Finally, one of the most important question is how do you validate a system whose outputs are non-deterministic? Standard Computer System Validation approaches in pharma assume you can define expected outputs for a given input. Agentic systems do not work that way and many use cases are still being worked out on what validation looks like for these systems. Organizations that are not thinking about this now will face it as a blocker when they try to move to production.
The mistake is treating the agent as the product. In pharma, the product is the workflow. The agent only creates value when it is embedded into the real work of evidence synthesis, launch planning, medical review, market monitoring, regulatory intelligence, KOL engagement, or field force enablement.
So, a stronger approach is to place the agent that is connected to the right data, governed by the right controls, reviewed by the right experts, and measured against the right business outcomes, to later become an operating infrastructure.
When we talk about architecture, Agentic AI is not a new feature sitting on top of an existing technology stack. It is a new stack. A production-grade agentic system has several layers that need to be designed deliberately:
- A data layer that defines what the agent can see, how that data is governed, and how its lineage and quality are tracked; a model layer that handles the underlying LLMs, fine-tuned models, and embedding systems
- An agent and tool layer where single agents, multi-agent networks, and reasoning loops operate and call external tools, APIs, and data sources
- An orchestration layer that manages task decomposition, agent coordination, and memory including short-term memory within a session, long-term memory that persists across sessions and shared memory that multiple agents can access simultaneously
- An observation layer that logs every decision, every tool call, every data source accessed, and every output produced
- A UI and engagement layer that defines how humans interact with, review, and override the system.
Cutting across all of these layers are two non-negotiable rails: security and compliance, and governance and audit. The challenge I see most often is that organizations treat these as separate workstreams managed by separate teams but in an agentic system, these layers are deeply interdependent. A gap in the data layer creates a problem in the observation layer and a gap in the observation layer makes the governance layer impossible to operate. One emerging standard worth understanding is MCP which is basically an agent-to-tool communication what HTTP did for the web establishing a common interface so that agents built on different platforms can connect to tools and data sources without bespoke integration for every combination.
Focus Is Key
Trying to make AI touch everything at once is exciting. Unfortunately, it usually translates into dozens of pilots, overlapping initiatives, impressive slides, and limited production impact.
This maintains teams busy, with the feeling of riding the AI wave, but in reality value remains scattered. Pharma leaders should stop launching disconnected experiments and choose a small number of high-impact workflows tied directly to business value. These could include:
- AI copilots for competitive intelligence and market monitoring: Commercial intelligence agents that surface competitor label changes, trial readouts and pricing moves in real time reducing the lag between signal and strategy update from weeks to hours, and replacing the quarterly slide deck that is already outdated by the time it is presented.
- Automated literature reviews and evidence synthesis: Evidence synthesis tools that screen and extract data from scientific literature in hours rather than weeks freeing medical affairs teams from the manual work of literature reviews that currently consume analyst time that should be going into interpretation and recommendation.
- AI-assistedHTA Filing and Dossier Generation: Extracting PICO-structured data, flagging evidence gaps against each body's specific threshold criteria and surfacing the indirect comparison analyses that are almost always the thing that delays a submission because the bottleneck in HTA is rarely the evidence itself.
- Medical content generation with compliance review workflows: Medical content drafting agents connected to approved sources, with built-in compliance review workflows, so that the time between response and approved is measured in hours rather than weeks.
- Predictive analytics for launch readiness and patient targeting: Launch readiness analytics that synthesize patient identification data, HCP engagement signals and market access indicators into a single view replacing the manual process of pulling five reports and reconciling them in a spreadsheet the night before a review meeting.
- Omnichannel personalization for HCP engagement: Analysing which clinical topics and sub-topics drive engagement versus unsubscribes by specialty and feeding those signals directly back into content generation.
Do not rank Agentic AI use cases by how innovative they sound. Rank them by whether they can survive production.
A pharma workflow is a strong Agentic AI candidate only if five things are clear from the start: the business owner, the approved data sources, the human approval point, the system it must integrate with, and the KPI it is expected to move. If a team cannot name those five things, the use case is not ready to scale.
That means moving away from broad ideas like “an AI copilot for Medical Affairs” and toward specific workflow bets, such as:
- reducing the time required to screen and extract evidence from scientific literature;
- accelerating competitive intelligence updates for a priority brand;
- shortening launch-readiness reporting cycles;
- improving KOL identification beyond existing relationship networks;
- supporting medical content drafts that move through approved compliance review.
A simple test for leaders is this: Can this agent improve one measurable workflow within 90 days without creating unacceptable compliance, quality, or adoption risk? If the answer is no, keep the idea in discovery. If the answer is yes, fund it like a production initiative: with integration, governance, validation, change management, and adoption metrics built in from day one.
Trust Is Not a Feeling. It Is an Operating Model.
Pharma skepticism toward AI is earned, since leaders have seen transformation programs overpromise. They have seen AI outputs that sounded confident, but could not be trusted, traced, or defended: a deal-breaker.
Trust is earned as the organization can see how the answer was produced, which sources were used, who reviewed it, what controls were applied, and what happens when something goes wrong. Trust must be designed into the workflow from the beginning.
In pharma, the richest AI opportunities are also the riskiest: scientific evidence, clinical data, medical content, regulatory intelligence, patient engagement, and commercial decision-making. These workflows are high value because they are complex, and because of the same reason, they are hard to scale.
It is not about moving the fastest at any cost; it is about making AI safe, transparent, and useful enough for analysts to rely on it, and make deployment possible.
Where Evalueserve Is Different
The mission is to help pharma use AI in ways that are useful, governed, measurable, and ready for real work. Pharma needs a practical way to turn promising AI ideas into reliable operating models.
That requires connecting three agendas that often move separately:
- Business teams need faster insight generation, better content workflows, stronger research support, sharper analytics, and more effective decision-making.
- CIO, CISO, and CAIO teams need governance, compliance, integration, architecture, and control. They cannot let every function build its own disconnected AI workflow.
- CFOs need measurable impact. They need to see whether AI reduces cost per process, shortens cycle times, increases capacity, or improves business outcomes.
Evalueserve brings together domain expertise, AI-enabled workflows, human quality review, and managed delivery models to move AI beyond experimentation. The goal is not to build an agent and declare success. Designing the operating model around the agent: where it fits, who uses it, how teams govern it, how experts check quality, and how leaders measure impact.
What’s Next for Pharma Leaders
The path from pilot to production is a discipline:
- Prioritize a small number of high-impact use cases. Choose workflows tied to revenue growth, speed-to-insight, operational efficiency, launch performance, or risk reduction.
- Build cross-functional AI squads. AI adoption fails when innovation, IT, data science, commercial, medical, and regulatory teams work in silos. The right squad combines business owners, domain experts, analytics, technology, compliance, and workflow execution.
- Design for production from day one. Before funding a pilot, ask what production would require: integration, access control, validation, monitoring, user training, change management, and measurement.
- Embed AI into existing workflows. The goal should not be to create another portal people have to remember to use. The goal should be to bring intelligence into the processes where work already happens.
- Measure adoption, not just deployment. A launched tool is not the same as a changed workflow. Track usage, decision acceleration, quality improvement, cycle-time reduction, workflow integration, and business outcomes.
Finally, start before everything feels ready. No organization has complete clarity; you must stay willing to learn through execution while building the governance and quality systems that pharma requires.
Not more demos, not more sandboxes, not more “AI initiatives” that never touch the operating model.
- Can a medical team cut evidence review cycles from weeks to days?
- Can a commercial team detect competitor moves before the next quarterly planning meeting?
- Can regulatory teams reduce repetitive document work without weakening control?
That’s the real race.
